PFF Teal = 0+160+175 MAIN COLORS PFF Green = 120+162+47 Light Green = 193+216+47 Red = 242+102+73 HIGHLIGHT COLORS Light Grey = 220+220+210 Dark Grey =

Slides:



Advertisements
Similar presentations
Appraising a diagnostic test study using a critical appraisal checklist Mahilum-Tapay L, et al. New point of care Chlamydia Rapid Test – bridging the gap.
Advertisements

ATS Documents Review Approval and Publication Processes.
Structure, Process and Outcome Conundrum © Clinical Audit Support Centre.
Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society Featured Article: Elizabeth R. Seaquist,
Challenges in Conducting Multi-Center Clinical Studies: Results from the Rapid Empiric Treatment with Oseltamivir Study (RETOS) Kendra Thompson, Kelly.
Nursing Implementation: Using Concept Map Care Plans in the Health-Care Agency 楊麗玉金繼春.
Clinical Approaches to IPF: Diagnosis and Monitoring Kevin R. Flaherty, MD, MS Associate Professor Pulmonary and Critical Care Medicine University of Michigan.
Hamlet’s Delight New Guidelines for IPF
Cost-Conscious Care Presentation Follow-up Chest X-Ray in Patients Admitted for Community Acquired Pneumonia Huy Tran, PGY-2 12/12/2013.
Comprehensive Thoracic Oncology Program: COG Update CTOP Research Retreat David Nalepinski Director, Oncology Service Line & Business Operations May 23,
Criteria for Centres of Expertise for Rare Diseases in the EU following EUCERD Recommendations RARECARENet Project: Consensus meeting on.
Good Practice on Scale The past, present and future of Foot and Ankle Pathways in NHS GGC Elaine McLure Nicola Munro David Wylie.
Legal & Ethical Issues. Objectives At the completion of this session the participant will be able to: ◦ Describe the ethical principles associated with.
Idiopathic Pulmonary Fibrosis: Diagnosis and Understanding
Managing the Money Trail in the Research Environment Seth B. Whitelaw Compliance Officer, Global R&D GlaxoSmithKline 14 November 2002.
Linda Devereux Associate Director Merseyside and Cheshire Cancer Network - why we are here and what’s next!
Accountable Care Organizations: What is the role of the pathologist? What are the public policy implications?
PFF Teal = MAIN COLORS PFF Green = Light Green = Red = HIGHLIGHT COLORS Light Grey = Dark Grey =
Pulmonary Fibrosis Foundation Summit 2015
PFF Teal = MAIN COLORS PFF Green = Light Green = Red = HIGHLIGHT COLORS Light Grey = Dark Grey =
PFF Teal = MAIN COLORS PFF Green = Light Green = Red = HIGHLIGHT COLORS Light Grey = Dark Grey =
PFF Teal = MAIN COLORS PFF Green = Light Green = Red = HIGHLIGHT COLORS Light Grey = Dark Grey =
PFF Teal = MAIN COLORS PFF Green = Light Green = Red = HIGHLIGHT COLORS Light Grey = Dark Grey =
PFF Teal = MAIN COLORS PFF Green = Light Green = Red = HIGHLIGHT COLORS Light Grey = Dark Grey =
PFF Teal = MAIN COLORS PFF Green = Light Green = Red = HIGHLIGHT COLORS Light Grey = Dark Grey =
PFF Teal = MAIN COLORS PFF Green = Light Green = Red = HIGHLIGHT COLORS Light Grey = Dark Grey =
PFF Teal = MAIN COLORS PFF Green = Light Green = Red = HIGHLIGHT COLORS Light Grey = Dark Grey =
PFF Teal = MAIN COLORS PFF Green = Light Green = Red = HIGHLIGHT COLORS Light Grey = Dark Grey =
PFF Teal = MAIN COLORS PFF Green = Light Green = Red = HIGHLIGHT COLORS Light Grey = Dark Grey =
PFF Teal = MAIN COLORS PFF Green = Light Green = Red = HIGHLIGHT COLORS Light Grey = Dark Grey =
PFF Teal = MAIN COLORS PFF Green = Light Green = Red = HIGHLIGHT COLORS Light Grey = Dark Grey =
PFF Teal = MAIN COLORS PFF Green = Light Green = Red = HIGHLIGHT COLORS Light Grey = Dark Grey =
PFF Teal = MAIN COLORS PFF Green = Light Green = Red = HIGHLIGHT COLORS Light Grey = Dark Grey =
PFF Teal = MAIN COLORS PFF Green = Light Green = Red = HIGHLIGHT COLORS Light Grey = Dark Grey =
PFF Teal = MAIN COLORS PFF Green = Light Green = Red = HIGHLIGHT COLORS Light Grey = Dark Grey =
Florida Cancer Plan Phil Roland, MD FACS FACOG Florida State Chair A Commission on Cancer.
Gynaecological Oncology Patient Pathway Cecile Bergzoll Gynaecological Oncologist Wellington.
Depart. Of Pulmonology and Critical Care Medicine R4 백승숙.
Emerging Approaches to Treatment of IPF Gregory P. Cosgrove, MD Associate Professor, Pulmonary Division Assistant Director, Interstitial Lung Disease Program.
Rheumatology Mastery in Ankylosing Spondylitis
Lessons Learnt The demise of thoracic surgery (Part II)
EULAR Study Group on Systemic Lupus Erythematosus (SLE) Dimitrios T
Volume 116, Issue 5, Pages (November 1999)
Recent Advances in Idiopathic Pulmonary Fibrosis
NICE Guidance – Service delivery for patients with Sarcomas
Subjects characteristics
Current and future research topics
A National Survey of Pulmonary Fibrosis Patients and Caregivers
Pulmonary Rehabilitation and Readmission
Respiratory MCNs - Interstitial lung diseases
Kaplan–Meier survival curves of interstitial pneumonia with autoimmune features (IPAF) with usual interstitial pneumonia (UIP) pattern (on high-resolution.
Participative Process Reviews
Multidisciplinary Perspectives on Interstitial Lung Diseases
Changes in high-resolution computed tomography (HRCT) pattern over time. a) Idiopathic pulmonary fibrosis (IPF), increased specificity over time. Changes.
Consolidated Standards of Reporting Trials diagram
Michael E. Halkos, MD, Anthony A. Gal, MD, Faraz Kerendi, MD, Daniel L
Representative images of immunohistochemical staining of discoidin domain receptor (DDR)2 in interstitial lung disease (ILD) other than idiopathic pulmonary.
Structure Process Outcomes
Diagnostic criteria for idiopathic pulmonary fibrosis
Cindy Murray NP Princess Margaret Cancer Centre
Flowchart showing the requirement for starting, documenting and evaluating the effect on quality of life (QoL) of interdisciplinary best supportive care.
Telemedicine in Hematology &Oncology Care
Telemedicine in Hematology &Oncology Care
Patient case study 2—fibrotic uILD in the setting of IPAF
Longitudinal Temporal and Probabilistic Prediction of Survival in a Cohort of Patients With Advanced Cancer  Pedro E. Perez-Cruz, MD, MPH, Renata Dos.
ILD Registry in the UK: IPF & Sarcoidosis databases
IPF diagnosis: flexibility is a virtue
Working Together to Diagnose Idiopathic Pulmonary Fibrosis
Subtypes of ILD in pre-MDT and post-MDT cohorts.
Diagnostic algorithm for idiopathic pulmonary fibrosis (IPF).
Presentation transcript:

PFF Teal = MAIN COLORS PFF Green = Light Green = Red = HIGHLIGHT COLORS Light Grey = Dark Grey = Black = CLINICAL CARE: MULTIDISCIPLINARY DIAGNOSIS SESSION LEADERS: CHARLENE D. FELL, MD, MSC MARVIN I. SCHWARZ, MD

PFF Teal = MAIN COLORS PFF Green = Light Green = Red = HIGHLIGHT COLORS Light Grey = Dark Grey = Black = HOW TO ORGANIZE MDD IN THE REAL WORLD CHARLENE D. FELL, MD, MSC CLINICAL CARE: MULTIDISIPLINARY DIAGNOSIS NOVEMBER 14, 2015

How to organize an MDD in the real world Charlene D Fell Division of Respirology November 14, 2015

Disclosures  Research Grants  Roche (InterMune)  Scientific Advisory Board  Roche (InterMune)  Boehringer Ingelheim  Speaker’s Fees  Roche (InterMune)  Boehringer Ingelheim I have taken the appropriate steps to ensure that the use of third party material in this presentation falls under fair dealing or the educational exceptions in the Copyright Act (Canada).

Outline  Why organize an MDD Rounds?  The key players  When, where, and how  Documentation

How an ILD MDD Works

Idiopathic Interstitial Pneumonia What is the Effect of a Muldisciplinary Approach to Diagnosis? Flaherty KR et al. AJRCCM 2004; 170: Interobserver agreement among all participants at step 5: κ = 0.88 (0.81, 0.94)

Why organize a MDD Rounds?  A MDD is considered the gold standard in establishing the diagnosis in ILD  Diagnostic accuracy is improved with a multidisciplinary diagnosis  Making the correct diagnosis is critical in order to:  Educate and prognosticate  Treat appropriately  Anticipate and screen for comorbidities  Enroll into clinical trials

 What kinds of cases will be discussed? — All new cases of ILD? — All new cases of IIP? — All patients suspected of having IPF? — All patients being screened for participation in a clinical trial?  Will you review patients not seen at your centre?

 Who should be involved? + Clinician + Thoracic Radiology + Pulmonary Pathology + ILD Clinic Nurse + Fellows and trainees ± Rheumatology ± Thoracic Surgery  Chair (“Champion”) Organize rounds Take notes Timekeeper

 Radiology  Paul Burrowes  John Henry MacGregor  Tracy Elliot  Andy Lee  Carmen Lydell  Michael Bristow  Pathology  Margaret Kelly  Francis Green  Rheumatology  Sharon LeClercq  ILD Clinic RN  Kirk Mathison

 When? — Regularly scheduled  Where? — Projector and screen — Access to diagnostic imaging software — Access to projection microscope — Access to telehealth

 A mechanism to get the case list and pertinent clinical information to the MDD team.

MDD Case List Worksheet

 Documenting the Outcome of the MDD — Structured MDD note:  List of participants  Clinical question and DDx  Key radiographic features and DDx  Key pathologic features and DDx  Consensus Diagnosis and recommendations  Compensation  Evolution of your MDD

Thank you!